首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備

Ceritinib市場規模、佔有率和成長分析：按類型、治療應用、用途、最終用戶、分銷管道和地區分類 - 行業預測，2026-2033 年

市場調查報告書

商品編碼

2003757

Ceritinib市場規模、佔有率和成長分析：按類型、治療應用、用途、最終用戶、分銷管道和地區分類 - 行業預測，2026-2033 年

Ceritinib Market Size, Share, and Growth Analysis, By Type, By Therapeutic Use, By Application, By End User, By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2026年03月27日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2024 年全球Ceritinib市場價值為 4.231 億美元，預計到 2033 年將成長至 7.7133 億美元，而 2025 年為 4.5229 億美元，預測期（2026-2033 年）複合年成長率為 6.9%。

全球Ceritinib市場的主要驅動力是治療ALK重排非小細胞肺癌的需求，並利用標靶抑制劑顯著提高存活率。Ceritinib由諾華公司研發，透過將基因數據與有效治療相結合，尤其是在Crizotinib抗藥性患者中，色瑞替尼在精準醫療領域中脫穎而出。隨著診斷方法的普及和監管核准的擴大，市場格局正從依賴化療轉向生物標記主導的治療。這增強了處方信心，尤其是在Crizotinib抗藥性患者群體中。一個關鍵趨勢是，隨著指南的實施，分子檢測的增加擴大了ALK陽性患者群體。 ALK檢測的普及使得Ceritinib能夠更早使用，尤其是在中樞神經系統轉移患者。此外，更清晰的報銷模式和聯合治療的臨床試驗也進一步推動了市場成長。

全球Ceritinib市場促進因素

在全球範圍內，Ceritinib市場的主要促進因素之一是ALK陽性非小細胞肺癌（NSCLC）發病率的上升，這推動了對標靶治療的需求成長。隨著人們對這種基因突變的認知和診斷水平的提高，越來越多的患者被發現能夠從強效ALK抑制劑Ceritinib獲益。此外，正在進行的研究和臨床試驗正在探索Ceritinib與其他治療方法聯合應用的療效，這進一步促進了其在臨床實踐中的應用。隨著精準醫療的日益普及，預計該藥物在腫瘤領域的市場佔有率將持續成長。

全球Ceritinib市場的限制因素

全球Ceritinib市場的主要限制因素是其高成本，這可能會限制進行性肺癌患者獲得治療的機會。嚴格的監管流程和因地區而異的醫療保險覆蓋範圍要求進一步加劇了這一經濟障礙。此外，替代療法的出現可能會促使醫療服務提供者選擇價格較低的治療方法，從而進一步限制Ceritinib的市場滲透率。再者，患者對Ceritinib的認知和教育方面仍有挑戰，這可能導致該藥物使用不足，最終影響市場的成長潛力。

全球Ceritinib市場趨勢

全球Ceritinib市場正呈現顯著上升趨勢，這主要得益於腫瘤標靶治療的日益普及。隨著生物標記和伴隨診斷技術的進步，患者篩選更加精準，腫瘤科醫師也擴大將Ceritinib替尼納入治療通訊協定，從而推動精準醫療的發展。隨著臨床醫師對Ceritinib的了解不斷加深，其應用信心也日益增強，尤其是在治療早期和小規模病例中。此外，製藥公司與診斷試劑生產商之間的協同合作也進一步鞏固了該藥物的市場地位。持續進行的臨床試驗和宣傳活動對於確立Ceritinib的療效至關重要，透過確立其在肺癌個體化治療策略中的核心地位，進一步鞏固其在全球腫瘤領域的領先地位。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太國家
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲國家
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲國家

競爭資訊

前五大公司對比
主要企業2025年的市場定位
主要市場公司採取的策略
近期市場趨勢
企業市場占有率分析，2025 年
主要企業的完整公司簡介
- 公司詳情
- 產品系列分析
- 按細分市場進行企業市佔率分析
- 銷售收入年比比較（2023-2025 年）

主要企業簡介

Novartis
Pfizer
Takeda
Roche
Eli Lilly
Merck & Co.
AstraZeneca
GlaxoSmithKline
Amgen
Bristol-Myers Squibb
Johnson & Johnson
Sanofi
Biogen
AbbVie
Astellas Pharma
Teva Pharmaceuticals
Regeneron Pharmaceuticals
Celgene
Incyte Corporation
Gilead Sciences

結論與建議

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太國家
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲國家
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲國家

競爭資訊

前五大公司對比
主要企業2025年的市場定位
主要市場公司採取的策略
近期市場趨勢
企業市場占有率分析，2025 年
主要企業的完整公司簡介
- 公司詳情
- 產品系列分析
- 按細分市場進行企業市佔率分析
- 銷售收入年比比較（2023-2025 年）

主要企業簡介

Novartis
Pfizer
Takeda
Roche
Eli Lilly
Merck & Co.
AstraZeneca
GlaxoSmithKline
Amgen
Bristol-Myers Squibb
Johnson & Johnson
Sanofi
Biogen
AbbVie
Astellas Pharma
Teva Pharmaceuticals
Regeneron Pharmaceuticals
Celgene
Incyte Corporation
Gilead Sciences

結論與建議

簡介目錄

Product Code: SQMIG35I2569

Global Ceritinib Market size was valued at USD 423.1 Million in 2024 and is poised to grow from USD 452.29 Million in 2025 to USD 771.33 Million by 2033, growing at a CAGR of 6.9% during the forecast period (2026-2033).

The global ceritinib market is primarily fueled by the necessity to address ALK rearranged non-small cell lung cancer, leveraging targeted inhibitors that significantly improve survival outcomes. Developed by Novartis, ceritinib stands out in the precision medicine landscape by translating genetic data into effective treatments, particularly for patients resistant to crizotinib. The market has shifted from chemotherapy reliance to biomarker-driven care, supported by increasing diagnostic adoption and regulatory approvals, which enhance prescribing confidence, especially in crizotinib-resistant cohorts. A major trend is the rise in molecular testing in conjunction with guideline implementation, broadening the ALK-positive patient base. The prevalence of ALK testing facilitates earlier ceritinib use, particularly for patients with central nervous system metastases, while clearer reimbursement models and combined therapy trials further propel market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Ceritinib market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Ceritinib Market Segments Analysis

Global ceritinib market is segmented by type, therapeutic use, application, end user, distribution channel and region. Based on type, the market is segmented into 50 capsules/box, 90 capsules/box and 150 capsules/box. Based on therapeutic use, the market is segmented into first-line treatment, second-line treatment and refractory cases. Based on application, the market is segmented into hospital, clinic, pharmacy and others. Based on end user, the market is segmented into public healthcare, private healthcare and research institutes. Based on distribution channel, the market is segmented into direct sales, pharmacy chains and online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Ceritinib Market

One of the key market drivers for the global Ceritinib market is the rising incidence of ALK-positive non-small cell lung cancer (NSCLC), which has led to an increased demand for targeted therapies. As awareness and diagnosis of this genetic mutation improve, more patients are being identified who can benefit from Ceritinib, a potent ALK inhibitor. Additionally, ongoing research and clinical trials exploring the efficacy of Ceritinib in combination with other treatment modalities are further propelling its uptake in clinical settings. The growing emphasis on personalized medicine will likely continue to enhance its market presence in oncology.

Restraints in the Global Ceritinib Market

A significant market restraint for the global ceritinib market is the high cost associated with the drug, which can limit accessibility for patients requiring treatment for advanced lung cancer. This financial barrier is compounded by the stringent regulatory processes and the necessity for health insurance coverage, which varies widely across regions. Furthermore, the availability of alternative therapies may lead healthcare providers to opt for less expensive treatments, further constraining ceritinib's market penetration. Additionally, ongoing challenges related to patient awareness and education about ceritinib may result in underutilization, ultimately impacting its market growth potential.

Market Trends of the Global Ceritinib Market

The global ceritinib market is experiencing a notable upward trend characterized by the expanding adoption of targeted therapies in oncology. As biomarkers and companion diagnostics enhance patient selection, oncologists are increasingly integrating ceritinib into treatment protocols, fostering precision medicine. Improved clinician familiarity is driving greater confidence in ceritinib's application, particularly in earlier treatment stages and smaller patient populations. Furthermore, synergistic collaborations between pharmaceutical and diagnostic companies are bolstering its market presence. Ongoing clinical trials and educational initiatives are pivotal in establishing ceritinib's efficacy, positioning it as a cornerstone in personalized treatment strategies for lung cancer, thus solidifying its role in global oncology.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index 2025
PESTEL Analysis
Regulatory Landscape

Global Ceritinib Market Size by Type & CAGR (2026-2033)

Market Overview
50 Capsules/Box
90 Capsules/Box
150 Capsules/Box

Global Ceritinib Market Size by Therapeutic Use & CAGR (2026-2033)

Market Overview
First-line Treatment
Second-line Treatment
Refractory Cases

Global Ceritinib Market Size by Application & CAGR (2026-2033)

Market Overview
Hospital
Clinic
Pharmacy
Others

Global Ceritinib Market Size by End User & CAGR (2026-2033)

Market Overview
Public Healthcare
Private Healthcare
Research Institutes

Global Ceritinib Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Direct Sales
Pharmacy Chains
Online Pharmacies

Global Ceritinib Market Size & CAGR (2026-2033)

North America (Type, Therapeutic Use, Application, End User, Distribution Channel)
- US
- Canada
Europe (Type, Therapeutic Use, Application, End User, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Therapeutic Use, Application, End User, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Therapeutic Use, Application, End User, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Therapeutic Use, Application, End User, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Novartis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celgene
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Incyte Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments